# Formulations Inteded to Deter Manipulation, Tampering, and Abuse
Also known as *abuse-deterrant formulations (ADFs)*, these medicines are generally engineered to be difficult to crush or have other aversion properties that deter consumption in ways other than intended. Pharmaceutical deterrence strategies include physical and chemical barriers, agonist/antagonist, aversion, prodrugs and new molecules, and drug delivery systems ([Tables 1-2 for overview](https://www.painphysicianjournal.com/current/pdf?article=NDcxMA%3D%3D&journal=108) and [presentation](https://www.fda.gov/media/101970/download)).<br>
<br>

_____

## A note on terminology and stigma

The term *abuse* is freuently used when discussing data related to controlled substances. It refers to the intentional, non-therapeutic use of a drug product or substance,
even once, to achieve a desired psychological or physiological effect. We recognize that some language can perpetuate stigma and negative bias toward individuals with substance use disorders and create barriers to effective treatment. For example, the term *abuse* [has been identified by NIH](https://www.drugabuse.gov/nidamed-medical-health-professionals/health-professions-education/words-matter-terms-to-use-avoid-when-talking-about-addiction) as having a high association with negative judgments and punishment. The term *abuse* is used here to describe a specific behavior that confers a risk of adverse health outcomes; it is not intended to imply moral judgment. We have retained the term because of its common usage in the field and expected use as a search term.

_____

[Detailed study overview](https://www.opioiddata.org/studies/counfounding-opioid-safety-studies/) at the full project site [OpioidData.org](https://www.opioiddata.org)
<br>
See [FDA Guidance](https://www.fda.gov/media/84819/download) on evaluation of abuse-deterrent formulations for eligibility criteria for labeling.
<br>
_____

##### **Full list of NDCs for abuse-deterrent formulations of opioids for analytic purposes can be found [here](ADF_NDCs.csv)**

_____

This document was updated November 6, 2020.
_____

### Abuse-Deterrent Formulations - Approved

|Drug Name|NDA#|[Categories of Evidence](https://www.fda.gov/media/84819/download)|Intended Route of Deterrence|Documentation|Status|ER/IR|ADF Label?|
|---|---|-----------|---------|--------|---|---|---|
|OxyContin|22-272|Categories 1-3, Category 4 possible|Intravenous, intranasal|[Drugs@FDA: OxyContin](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022272)<br><br>[FDA AdCom: September 10-11, 2020](https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-10-11-2020-joint-meeting-drug-safety-and-risk-management-advisory-committee-and-anesthetic#event-materials)<br><br>[OxyContin NDCs](OxyContin/oxycontin_NDCs.csv)<br><br>[OxyContin Documentation](OxyContin)|Active|ER|Yes|
|Hysingla ER|206627|**Intranasal & oral:** Category 1, Category 3<br>**Injection:** Category 1|Intravenous, intranasal, oral|[Drugs@FDA: Hysingla ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206627)<br><br>[Hysingla NDCs](Hysingla_ER/hysingla_NDCs.csv)<br><br>[Hysingla Documentation](Hysingla_ER)|Active|ER|Yes|
|MorphaBond ER|206544|**Injection:** Category 1<br>**Intranasal:** Category 1, Category 3|Intravenous, intranasal|[Drugs@FDA: MorphaBond ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206544)<br><br>[MorphaBond NDCs](MorphaBond_ER/morphabond_NDCs.csv)<br><br>[MorphaBond Documentation](MorphaBond_ER)|Discontinued|ER|Yes|
|Xtampza ER|208090|Categories 1-3|Intravenous, intranasal, oral|[Drugs@FDA: Xtampza ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208090)<br><br>FDA AdCom: September 11, [2015](https://wayback.archive-it.org/7993/20170403223626/https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/ucm433361.htm)<br><br>[Xtampza NDCs](Xtampza_ER/xtampza_NDCs.csv)<br><br>[Xtampza Documentation](Xtampza)|Active|ER|Yes|
|RoxyBond|209777|Categories 1-3|Intravenous, intranasal|[Drugs@FDA: RoxyBond](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209777)<br><br>FDA AdCom: April 5, [2017](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2017-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[RoxyBond Documentation](RoxyBond)|Discontinued|IR|Yes: Intravenous, intranasal|
|Embeda|022321|**Oral & Intranasal:** Category 1, Category 2, Category 3|Oral, intranasal|[Drugs@FDA: Embeda](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022321)<br><br>[Embeda NDCs](Embeda/embeda_NDCs.csv)<br><br>[Embeda Documentation](Embeda)|Discontinued|ER|Yes|
|Arymo ER|208603|Categories 1-3|Oral, intravenous, intranasal|[Drugs@FDA: Arymo ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208603)<br><br>FDA AdCom: August 4, [2016](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2016-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[Arymo NDCs](Arymo_ER/arymo_NDCs.csv)<br><br>[Arymo Documentation](Arymo)|Discontinued|ER|Yes: Oral, intravenous, intranasal|
|Targiniq|205777|Category 1, Category 3|Intravenous, intranasal|[Drugs@FDA: Targiniq](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205777)<br><br>[Targiniq Documentation](Targiniq)|Discontinued|ER|Yes|
|Troxyca ER|207621|Category 1, Category 2, Category 3|Oral, intranasal|[Drugs@FDA: Troxyca ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207621)<br><br>FDA AdCom: June 8, [2016](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2016-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[Troxyca Documentation](Troxyca)|Discontinued|ER|Yes:Oral, intranasal, intravenous|
|Vantrela ER|207975|Categories 1-3|Oral, intranasal, intravenous|[Drugs@FDA: Vantrela ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207975)<br><br>FDA AdCom: June 7, [2016](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2016-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[Vantrela ER Documentation](Vantrela_ER)|Inactive|ER|Yes: Oral, intranasal, intravenous|

_____


### Abuse-Deterrent Formulations - Unsuccessful Applications

|Drug Name|NDA#|Categories of Evidence|Intended Route of Deterrence|Documentation|Status|ER/IR|ADF Label?|
|---|---|-----------|---------|--------|---|---|---|
|Oxaydo/Oxecta|202080|Category 3|Intranasal|[Drugs@FDA: Oxaydo](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202080)<br><br>[Oxaydo/Oxecta NDCs](Oxaydo/oxaydo_NDCs.csv)<br><br>[Oxaydo Documentation](Unsuccessful_applications/Oxaydo)|Active|IR|No|
|Oxycodone HCl ER with blue dye (Aximris XR)|209653|Categories 1-3|Oral, intravenous, intranasal|[FDA AdCom: January 15, 2020](https://www.fda.gov/advisory-committees/advisory-committee-calendar/january-15-2020-joint-meeting-anesthetic-and-analgesic-drug-products-advisory-committee-and-drug)<br><br>FDA AdCom: July 26, [2017](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2017-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[Aximris XR Documentation](Unsuccessful_applications/Aximris_XR)|Inactive|ER|No|
|Opana ER|201655|Categories 1-4|Intranasal, intravenous|[Drugs@FDA: Opana ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=201655)<br><br>FDA AdCom: March 13-14, [2020](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2017-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[Opana Documentation](Unsuccessful_applications/Opana_ER)|Inactive|ER|No|
|Apadaz|208653|Categories 1-3|Oral, intranasal, intravenous, smoking|[Drugs@FDA: Apadaz](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208653)<br><br>FDA AdCom: May 5, [2016](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2016-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[Apadaz Documentation](Unsuccessful_applications/Apadaz)|Inactive|IR|No|
|Remoxy ER|22324|Categories 1-3|Intranasal, intravenous, smoking|FDA AdCom: June 26, [2018](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2018-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[Remoxy ER Documentation](Unsuccessful_applications/Remoxy_ER)|Inactive|ER|No|
|Avridi|206830|Categories 1-3|Intranasal, intravenous|FDA AdCom: September 10, [2015](https://wayback.archive-it.org/7993/20170403223626/https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/ucm433361.htm)<br><br>[Avridi Documentation](Unsuccessful_applications/Avridi)|Inactive|IR|No|

_____


### Historical and Pre-market Products 

Two older products in particular influenced the modern conceptualization of abuse deterrent formulations: [Talwin NX](https://pubmed.ncbi.nlm.nih.gov/3112855/) and Suboxone.
<br><br>
Many earlier development projects did not result in products brought to market: ReXista, DETERx, OROS Hydromorphone, OxyNal, Oxytrex, etc. ([Table 1](https://academic.oup.com/view-large/28240821), [full citation]( https://academic.oup.com/painmedicine/article/10/suppl_2/S124/1836911)) for a partial list.<br><br>
We are interested in listing publicly acknowledged pharmaceutical development efforts for new products that may fall in this category. 
